- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03241888
Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia
Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After diagnosed of endometrial atypical hyperplasia (EAH) by hysteroscopy, patients will be enrolled. Age, waist circumstances, blood pressure, basic history of infertility, blood pressure, serum lipid level and side effects will be collected. Blood tests, including fasting blood glucose (FBG), postprandial blood glucose (PBG), fasting insulin (FINS), SHBG, sex hormone levels, blood lipids and anti-müllerian hormone(AMH) will be performed before treatment to evacuate their metabolic conditions.
Patients are randomized to 1 of 3 treatment groups. Patients will receive MA (megestrol acetate) 160 mg by mouth daily for at least 3 months on Arm I. Patients will receive LNG-IUS insertion on Arm II and MA 160 mg plus LNG-IUS insertion on Arm III. Then an hysteroscope will be used to evaluate the endometrial condition every 3 months, and the findings will be recorded. For patients with EAH, complete response (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypia; no response (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of endometrial cancer in patients. Continuous therapies will be needed in PR, NR or PD.
After completion of study treatment, 2 months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200011
- Obstetrics and Gynecology Hospital, Fudan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Primarily have a confirmed diagnosis of endometrial atypical hyperplasia based upon hysteroscopy
- Have a desire for remaining reproductive function or uterus
- Need to be able to undergo correlative treatment and follow-up
Exclusion Criteria:
- Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
- Pregnancy or suspicion of pregnancy
- Have a history of EAH and have disease relapse during Merina insertion
- Under treatment of high-dose progestin therapy more than 3 months in recent 6 months
- Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity
- Confirmed diagnosis of malignant tumor in genital system
- Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
- Hypersensitivity or contradiction to any component of this product
- Ask for removal of the uterus or other conservative treatment
- Smoker(>15 cigarettes a day)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: MA
Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
|
At a dosage of 160 mg/day
Other Names:
|
Active Comparator: LNG-IUS
Patients will receive LNG-IUS insertion for at least 3 months.
Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
|
Active ingredient: levonorgestrel 52mg.
It is a hormone-releasing T-shaped intrauterine system.
Other Names:
|
Experimental: MA+LNG-IUS
Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months.
Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
|
At a dosage of 160 mg/day
Other Names:
Active ingredient: levonorgestrel 52mg.
It is a hormone-releasing T-shaped intrauterine system.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological response rate
Time Frame: From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
|
From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
|
|
Pathological response time
Time Frame: From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
|
time of histologic regression from endometrial atypical hyperplasia to benign endometrium
|
From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: up to 2 years after the treatment for each patient
|
Common side effects from these drugs include weight gain, vaginal spotting and descent of sexuality.
Severe side effects include thrombus and diseases related.
The investigators will record any mental or body symptoms and evaluate the correlation.
|
up to 2 years after the treatment for each patient
|
Rate of relapse
Time Frame: up to 2 years after the treatment for each patient
|
up to 2 years after the treatment for each patient
|
|
Rate of pregnancy
Time Frame: up to 2 years after the treatment for each patient
|
up to 2 years after the treatment for each patient
|
|
Compliance
Time Frame: up to 2 years after the treatment for each patient
|
The investigators designed a questionnaire to evaluate the compliance through treatment as side effects of oral megestrol acetate may be more common than LNG-IUS.
Self Efficacy, physical activity and social support will be scored (1 to 5) and compared among each arm.
|
up to 2 years after the treatment for each patient
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Economic consequences through study completion
Time Frame: From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
|
The investigators will evaluate whether the combination could shorten the therapeutic period, so that bring economic benefits.
|
From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014 Mar;121(4):477-86. doi: 10.1111/1471-0528.12499. Epub 2013 Nov 28.
- Mittermeier T, Farrant C, Wise MR. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia. Cochrane Database Syst Rev. 2020 Sep 6;9(9):CD012658. doi: 10.1002/14651858.CD012658.pub2.
- Gressel GM, Parkash V, Pal L. Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. Int J Gynaecol Obstet. 2015 Dec;131(3):234-9. doi: 10.1016/j.ijgo.2015.06.031. Epub 2015 Sep 8.
- Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, Nam JH. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013 Mar;49(4):868-74. doi: 10.1016/j.ejca.2012.09.017. Epub 2012 Oct 13.
- Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, Tjalma W. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas. 2007 Jun 20;57(2):210-3. doi: 10.1016/j.maturitas.2006.12.004. Epub 2007 Jan 31.
- Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002 Apr;186(4):651-7. doi: 10.1067/mob.2002.122130.
- Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int J Gynaecol Obstet. 2016 Jan;132(1):34-8. doi: 10.1016/j.ijgo.2015.06.046. Epub 2015 Oct 1.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Uterine Diseases
- Hyperplasia
- Endometrial Hyperplasia
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Central Nervous System Stimulants
- Appetite Stimulants
- Levonorgestrel
- Megestrol
- Megestrol Acetate
Other Study ID Numbers
- 2017-30-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atypical Endometrial Hyperplasia
-
IRCCS Burlo GarofoloCompletedAtypical Endometrial Hyperplasia | Atypical Endometrial PolypsItaly
-
Zagazig UniversityCompletedAtypical Endometrial HyperplasiaEgypt
-
Fudan UniversityTerminatedAtypical Endometrial HyperplasiaChina
-
West China Second University HospitalRecruitingAtypical Endometrial Hyperplasia | Endometrial CancerChina
-
Xiaojun ChenHuashan HospitalWithdrawnAtypical Endometrial Hyperplasia | Fertility Issues | Obese
-
Peking University People's HospitalPeking University; Beihang UniversityRecruitingAtypical Endometrial Hyperplasia | Endometrial Carcinoma Stage IChina
-
Krankenhaus Barmherzige Schwestern LinzCompletedEndometrial Cancer | Atypical HyperplasiaAustria
-
NYU Langone HealthCompletedAtypical Endometrial Hyperplasia | Endometrial CarcinomaUnited States
-
Peking University People's HospitalRecruitingAtypical Endometrial Hyperplasia | Endometrial Carcinoma Stage IChina
-
Fudan UniversityCompletedAtypical Endometrial HyperplasiaChina
Clinical Trials on Megestrol Acetate
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBreast Cancer | Hot Flashes
-
Xiaojun ChenZhejiang Cancer Hospital; Fudan University; Shanghai 6th People's Hospital; Shanghai...CompletedEndometrial Adenocarcinoma | Endometrial Atypical HyperplasiaChina
-
Par Pharmaceutical, Inc.PRA Health SciencesTerminatedAnorexia | Weight Loss | CachexiaUnited States
-
Bristol-Myers SquibbCompletedHIV Infections | Anorexia | CachexiaUnited States
-
Bristol-Myers SquibbCompletedHIV Infections | Anorexia | CachexiaUnited States
-
Endo PharmaceuticalsQuintiles, Inc.CompletedHIV Infections | Anorexia | Cachexia | HIV Wasting Syndrome | AIDS Wasting SyndromeUnited States, India, South Africa
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAnorexia | Lung Cancer | CachexiaUnited States
-
St. Vincent Medical Center - Los AngelesUnknownBreast Cancer | Malignant Mesothelioma | Endometrial CancerUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedFatigue | Unspecified Adult Solid Tumor, Protocol Specific | CachexiaUnited States
-
Bristol-Myers SquibbCompletedHIV Infections | Anorexia | CachexiaUnited States